Aloe vera for Prevention of Acute Radiation Proctitis in Colorectal Cancer: A Preliminary Randomized, Placebo-Controlled Clinical Trial

2020 ◽  
Author(s):  
Ebrahim Salehifar ◽  
adeleh sahebnasagh ◽  
fatemeh saghafi ◽  
abbas alipour ◽  
Arash Ghasemi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Aloe Vera ◽  
Acute Radiation ◽  
Radiation Proctitis ◽  
Lower Probability ◽  
Rectal Pain ◽  
Colorectal Cancer Patients ◽  
Subject Differences

Abstract Background Acute radiation proctitis (ARP) is a common complication of radiation therapy (RT). This adverse effect in severe cases ultimately results in interruption of RT and poor outcome. Aloe vera contains multiple antioxidant and anti-inflammatory compounds This study was aimed to evaluate the preventive effects of Aloe vera in ARP in colorectal cancer.Method: twenty eligible colorectal cancer patients, who received radiation, were randomized to receive Aloe vera 3% ointment or placebo for six weeks. At each weekly visit, ARP symptoms were evaluated by Radiation Therapy Oncology Group (RTOG) and clinical presentation criteria. The lifestyle impact of the symptoms, depression and anxiety for assessment of psychosocial status of patients, and quantitative CRP were evaluated as secondary endpoints.Results there was a significant improvement in the symptom index for diarrhea and total RTOG scores and quantitative CRP levels (between-subject differences or group effect) (p < 0.05) in Aloe group. The overall time trend (within-subject differences or time effect) was statistically significant for rectal bleeding, rectal pain, total clinical scores, proctitis, cystitis, and total RTOG (P < 0.05) in Aloe vera group. The median lifestyle score improved significantly with Aloe vera. Intervention patients had a lower probability of presenting anxiety in their overall HAD scale during RT.Conclusion The use of topical formulation of Aloe vera 3% diminished the severity of ARP in colorectal cancer patients. Trial registration: Current Controlled Trials IRCT201606042027N6, registrations date: 2016-04-09.

scholarly journals Provisional Clinical Opinions for Radiation Therapy in Prefrail Elderly Colorectal Cancer Patients: Part One

2021 ◽  
Vol 74 (7) ◽  
pp. 413-421
Author(s):  
Keiko Murofushi ◽  
Yuji Murakami ◽  
Hirokazu Makishima ◽  
Toshikazu Moriwaki ◽  
Takeshi Sasaki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Provisional Clinical Opinions for Radiation Therapy in Prefrail Elderly Colorectal Cancer Patients: Part Two

2021 ◽  
Vol 74 (7) ◽  
pp. 422-429
Author(s):  
Keiko Murofushi ◽  
Yuji Murakami ◽  
Hirokazu Makishima ◽  
Toshikazu Moriwaki ◽  
Takeshi Sasaki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

Stereotactic body radiotherapy response and local control rates for hepatic oligometastases.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3546-3546
Author(s):  
Ben Goodman ◽  
Cynthia S Johnson ◽  
Netsanet Gebregziabher ◽  
Mary A. Maluccio ◽  
Paul R. Helft ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Local Control ◽  
Stereotactic Body Radiation Therapy ◽  
Local Control Rate ◽  
Primary Cancer ◽  
Stereotactic Body Radiation ◽  
The Mean ◽  
Colorectal Cancer Patients

3546 Background: Stereotactic body radiation therapy (SBRT) is a non-invasive, effective technique in the treatment of hepatic oligometastases from solid tumors. We present response and local control rates from our single institution experience. Methods: We treated 79 metastatic liver lesions from 64 different patients using stereotactic body radiation therapy. One colorectal cancer patient was treated three times and four patients were treated twice. Among the 79 metastatic liver lesions treated, 85% had prior chemotherapy. The primary cancer site included: Colorectal 66%, Non-colorectal GI 14%, Breast 6%, Ovarian 5%, NSCLC 3%, and other 6%. The mean GTV size was 37.3 (cc). The mean GTV diameter was 3.1 (cm). The median total dose was 54 (Gy) with the minimum and maximum total dose being 30 and 60 (Gy). Results: The overall local control rate was 94.2%, with estimates at 12, 24, 36, and 48 months being 96.1%, 87.9%, 87.9% and 87.9% following SBRT treatment. When comparing colorectal cancer patients vs all other primary cancer sites, the one year local control rate was 93.4% and 100%. The two and three year local control rates for colorectal cancer vs other primary cancer sites were 84.9% vs 90.9%. Best response was examined as a 4 level response (CR,PR,SD,PD) per the RECIST criteria. Overall, 67% of patients had a response, and less than 3% of patients had progression with SBRT treatment. For colorectal cancer patients, 79% had a response to treatment. Only 21% of colorectal cancer patients did not respond, however, the majority of these patients still had stable disease following treatment. Non-colorectal primary site cancers had a response in 50% of the lesions following SBRT treatment. The remaining 50% of non-colorectal primary cancers were stable following SBRT treatment and none progressed. The median dose for CR, PR, or SD was 54 Gy. The median dose for patients with progressive disease was less than 50 Gy. The observed CTC toxicities were limited with mostly grade 1-2 toxicity and only two grade 4 and one grade 5 toxicity. Conclusions: Stereotactic body radiation therapy is an effective treatment option for patients with hepatic oligometastases with a limited toxicity profile.

Prevalence, severity, and evolution of anemia in colorectal cancer patients receiving radiation therapy with/without chemotherapy: a retrospective analysis

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13510-13510
Author(s):  
K. Hu ◽  
D. Shasha ◽  
P. Homel ◽  
L. B. Harrison
Keyword(s):  
Colorectal Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Contributing Factors ◽  
Curative Intent ◽  
End Of Treatment ◽  
Evaluable Population ◽  
Pre Treatment ◽  
Colorectal Cancer Patients

13510 Background: Colorectal cancer (CRC) patients frequently present with anemia. Anemia may also develop or be exacerbated in CRC patients as a consequence of treatment with radiation therapy (RT) with or without (±) chemotherapy (CT). A better understanding of the relationship between anemia and RT ± CT is important as several studies have found that hemoglobin (Hb) levels are predictive of RT outcomes and that low Hb levels can diminish patient quality of life (QOL). However, the prevalence and evolution of anemia before and during RT ± CT are poorly characterized in CRC patients. Methods: Prospectively collected data from 81 CRC patients who received 10 weeks of curative-intent RT alone (26%) or in combination with CT (74%) were analyzed retrospectively to determine prevalence, severity, patterns and contributing factors of anemia. Results: Prior to RT ± CT, 38% of patients (n = 71, evaluable population) were anemic (defined as Hb ≤12 g/dL) and by the end of treatment, 61% were anemic (including 41% of patients not anemic and 93% anemic pre-treatment). A significant (P <.001) decrease in mean Hb for all patients was already apparent after <5 weeks RT ± CT, ie, from 12.6±2.0 g/dL to 11.5±1.8 g/dL, and the decrease in Hb remained consistent over time (see Table). The greatest Hb decrease was noted in patients not anemic pre-treatment, although not all became anemic. Multivariate analysis using logistic regression identified pre-treatment anemia (P = .0006) and age (P = .02) as the factors most strongly associated with intra-treatment anemia. Conclusions: Because anemia can adversely affect QOL and possibly also treatment outcomes in cancer patients, this condition needs to be addressed as part of the overall management of anemic colorectal cancer patients. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document